MEDESIS PHARMA : INCLUSION OF FIRST PATIENTS IN CLINICAL TRIAL IN BRAZIL ON NANOMANGANESE FOR THE TREATMENT OF SEVERE FORMS OF COVID-19
Subscribe

07 Feb 2022 17:45 CET

Company Name

MEDESIS PHARMA S.A.

ISN

FR0010844464

Market

Euronext Growth

Symbol

ALMDP

See attachment(s) / Voir document(s) joint(s) / Zie bijlage / Ver documento(s) em anexo

16165_1045847_MEDESISPHARMA_CP_NanoMnBresil_EN.pdf

Source

MEDESIS PHARMA

Provider

Les Echos

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Medesis Pharma SA published this content on 07 February 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 07 February 2022 17:09:03 UTC.